Is Gufic Biosciences Ltd (GUFICBIO) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gufic Biosciences Ltd is a average quality company .

Is Gufic Biosciences Ltd (GUFICBIO) undervalued or overvalued?

The key valuation ratios of Gufic Biosciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Gufic Biosciences Ltd (GUFICBIO) share price return in the past 10 years?

Gufic Biosciences Ltd share price has appreciated 22% annually (CAGR) over the past ten years.

Is Gufic Biosciences Ltd (GUFICBIO) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Gufic Biosciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Gufic Biosciences Ltd (GUFICBIO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Gufic Biosciences Ltd (GUFICBIO) on 17-Apr-2026 16:59:59 at 16:59 is 301.30.

What is the P/E ratio of Gufic Biosciences?

The latest standalone P/E ratio of Gufic Biosciences as of 17-Apr-2026 is 59.78.

What is the P/B ratio of Gufic Biosciences Ltd (GUFICBIO)?

The latest standalone P/B ratio of Gufic Biosciences Ltd (GUFICBIO) as of 17-Apr-2026 is 4.69.

What is the 52-week high and low of Gufic Biosciences Ltd (GUFICBIO)?

The 52-week high of Gufic Biosciences Ltd (GUFICBIO) is Rs. 409.00 and the 52-week low is Rs. 267.50.

Gufic Biosciences Ltd (GUFICBIO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Gufic Biosciences Ltd (GUFICBIO)
Brand: Gufic Biosciences

Gufic Biosciences Ltd (GUFICBIO) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Gufic Biosciences Ltd (GUFICBIO)

BSE: 509079 NSE: GUFICBIO

Key Metrics

Market Cap

₹3,022 Cr.

P/E Ratio

59.78

Price to Book (P/B)

4.69

Price to Sales (P/S)

3.38

EV/EBITDA

24.26

Return on Capital Employed (ROCE)

13.51%

Current Price

₹301.3

Return on Equity (ROE)

12.34%

Return on Assets (ROA)

6.18%

Operating Profit Margin

16.9%

Net Profit Margin

8.53%

Gross Profit Margin

10.5%

Book Value per Share

₹64.2

Sales Growth (YoY)

1.63%

Sales Growth (3 Years)

1.71%

Operating Profit Growth (1 Year)

-7.4%

Operating Profit Growth (3 Years)

-2.69%

Net Profit Growth (1 Year)

-18.82%

52-Week Low / High

₹268 / 409

Net Profit Growth (3 Years)

-9.97%

Dividend Yield

0.03%

Promoter Holding

72.50%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Gufic Biosciences Ltd?

Gufic Biosciences Ltd revenue growth is 1.6% for FY-2025 , which is below its 5 year CAGR of 16.7% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Gufic Biosciences Ltd?

Promoters hold 72.50% of the Gufic Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Gufic Biosciences Ltd vs industry peers?

Gufic Biosciences Ltd revenue CAGR is 16.69% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Gufic Biosciences Ltd belong to?

Gufic Biosciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Gufic Biosciences Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 21.5% based on the current price.

DeciZen - make an informed investing decision on Gufic Biosciences

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Gufic Biosciences stock performance

Key Ratios

Is Gufic Biosciences Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	24.2%	24.3%	34.1%	29.7%	21%	30.1%	47.3%	23.2%	17.6%	13.5%	-
Value Creation Index ⓘ	0.7	0.7	1.4	1.1	0.5	1.2	2.4	0.7	0.3	0.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	202	246	306	351	379	488	779	691	807	820	893
Sales YoY Gr.	-	21.4%	24.5%	14.8%	8%	28.7%	59.8%	-11.4%	16.8%	1.6%	-
Adj EPS ⓘ	1	1.1	1.9	2.8	2.4	4.5	9.8	8.4	8.7	7.1	5
YoY Gr.	-	12.1%	74.8%	43.3%	-15.1%	89%	120.4%	-14.2%	3.4%	-18.2%	-
BVPS (₹) ⓘ	4.4	4.8	7	9.7	13.3	17.9	27.8	35.9	53.1	60	64.2
Adj Net Profit ⓘ	7.6	8.6	15.1	21.7	22.9	43.2	95.3	81.8	87.4	71.5	51
Cash Flow from Ops. ⓘ	-4.3	-4.1	-4.8	5.2	47.1	87.3	106	-26.6	-7.5	123	-
Debt/CF from Ops. ⓘ	-9.9	-13.7	-16.5	18.8	2.5	0.6	0.6	-11.7	-42.5	2.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	16.8%	16.7%	1.7%	1.6%
Adj EPS ⓘ	24.5%	24.8%	-10.2%	-18.2%
BVPSⓘ	33.7%	35.1%	29.3%	12.9%
Share Price	22%	21.7%	15%	-12.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	25	24.2	33	33.5	22.3	28.5	43.1	26.5	19.9	12.6	8.1
Op. Profit Mgn % ⓘ	10	9.4	12.7	13.1	13.8	17.2	19	19.9	18.6	16.9	14.7
Net Profit Mgn % ⓘ	3.8	3.5	4.9	6.2	6	8.9	12.2	11.8	10.8	8.7	5.7
Debt to Equity ⓘ	1.3	1.5	1.5	1.3	0.9	0.3	0.2	0.9	0.6	0.5	-
Working Cap Days ⓘ	187	190	201	239	254	201	136	187	213	203	139
Cash Conv. Cycle ⓘ	40	67	86	73	84	47	31	55	91	83	51

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	5	5
TTM Sales (₹ Cr.)	893	897
BVPS (₹) ⓘ	64.2	64.2
Reserves (₹ Cr.) ⓘ	634	634
P/BV ⓘ	4.69	4.70
PE ⓘ	59.78	60.38

From the Market
52 Week Low / High (₹)	267.50 / 409.00
All Time Low / High (₹)	0.17 / 501.10
Market Cap (₹ Cr.)	3,022
Equity (₹ Cr.)	10
Face Value (₹)	1
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Gufic Biosciences - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	202	246	306	351	379	488	779	691	807	820
Operating Expenses ⓘ +	183	223	267	305	327	404	631	556	659	683
Manufacturing Costs	27	32	41	47	51	57	93	87	107	125
Material Costs	91	107	129	161	156	226	368	295	339	310
Employee Cost	32	41	45	47	59	66	86	87	110	127
Other Costs ⓘ	33	42	52	50	60	55	84	86	103	121
Operating Profit ⓘ	20	23	39	46	52	84	148	135	147	136
Operating Profit Margin (%)	9.7%	9.3%	12.7%	13.1%	13.8%	17.2%	19.0%	19.5%	18.3%	16.6%
Other Income ⓘ +	1	1	3	4	6	4	3	3	2	4
Exceptional Items ⓘ	0	0	2	0	0	0	0	0	0	0
Interest ⓘ	6	6	9	10	14	14	5	8	17	25
Depreciation ⓘ	4	4	4	5	14	16	19	22	17	21
Profit Before Tax ⓘ	10	14	30	35	30	58	127	107	116	94
Tax ⓘ	3	5	13	13	7	13	31	27	30	24
Profit After Tax	7	9	16	22	23	44	96	80	86	70
PAT Margin (%)	3.6%	3.7%	5.4%	6.3%	6.0%	9.1%	12.3%	11.5%	10.7%	8.5%
Adjusted EPS (₹)	1.0	1.2	2.1	2.8	2.3	4.6	9.9	8.2	8.6	7.0
Dividend Payout Ratio (%)	5%	4%	2%	2%	2%	2%	1%	1%	1%	1%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	34	37	54	75	129	173	269	348	533	601
Share Capital ⓘ	8	8	8	8	10	10	10	10	10	10
Reserves ⓘ	26	30	46	68	120	164	259	338	523	591
Debt +	40	54	77	96	113	52	55	302	296	285
Long Term Debt	8	7	8	11	20	35	48	191	154	130
Short Term Debt	32	47	69	85	93	16	7	112	142	154
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	53	44	76	78	117	111	141	130	166	159
Others Liabilities ⓘ	26	40	28	61	48	83	57	80	98	125
Total Liabilities ⓘ	152	175	235	310	407	419	521	860	1,093	1,170
Fixed Assets
Net Fixed Assets ⓘ +	22	22	23	24	83	100	115	160	159	506
Gross Block	51	26	31	37	115	149	180	246	246	614
Accumulated Depreciation	29	4	8	13	32	49	64	87	87	108
CWIP ⓘ	0	0	2	10	31	13	41	170	307	22
Investments ⓘ	0	0	0	0	0	0	0	1	2	3
Inventories	50	63	94	94	122	94	116	183	200	217
Trade Receivables	56	52	81	103	107	125	152	205	330	315
Cash Equivalents	6	6	7	8	16	13	27	47	13	28
Others Assets ⓘ	17	32	28	71	48	74	72	95	81	79
Total Assets ⓘ	152	175	235	310	407	419	521	860	1,093	1,170

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-4	-4	-5	5	47	87	106	-27	-7	123
PBT ⓘ	11	14	30	35	30	58	127	107	116	94
Adjustment ⓘ	9	10	12	13	25	31	23	30	34	44
Changes in Working Capital ⓘ	-21	-24	-30	-34	2	8	-11	-135	-130	7
Tax Paid ⓘ	-3	-5	-16	-10	-10	-9	-33	-28	-27	-23
Cash Flow From Investing Activity ⓘ +	-1	-5	-9	-13	-43	-7	-95	-191	-102	-72
Capex	-1	-4	-8	-13	-40	-12	-87	-188	-108	-71
Net Investments	0	0	0	0	0	0	0	-1	-1	-1
Others ⓘ	0	-1	-1	0	-3	6	-7	-2	7	-0
Cash Flow From Financing Activity ⓘ +	5	7	14	8	-4	-79	-6	234	82	-37
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	100	0
Net Proceeds from Borrowing ⓘ	-4	-1	1	3	7	12	12	107	-37	-24
Interest Paid ⓘ	-5	-6	-8	-10	-14	-13	-5	-8	-13	-21
Dividend Paid ⓘ	-0	-0	-0	-0	-0	-0	-1	-1	-1	-1
Others ⓘ	14	15	22	15	3	-77	-12	136	33	8
Net Cash Flow ⓘ	-0	-1	1	-0	0	2	5	17	-27	14

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	23.99	25.31	36.03	33.89	22.17	29.22	43.31	25.84	19.57	12.34
ROCE (%)	24.24	24.26	34.1	29.65	21.01	30.05	47.29	23.23	17.56	13.51
Asset Turnover Ratio	1.53	1.59	1.55	1.32	1.09	1.26	1.8	1.16	0.96	0.97
PAT to CFO Conversion(x)	-0.57	-0.44	-0.31	0.23	2.04	1.98	1.1	-0.34	-0.08	1.76
Working Capital Days
Receivable Days	76	76	76	93	98	81	59	81	104	107
Inventory Days	74	79	90	95	101	76	45	68	75	69
Payable Days	205	164	170	174	227	184	125	168	160	191

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gufic Biosciences Ltd FAQs

The current trading price of Gufic Biosciences on 17-Apr-2026 16:59 is ₹301.3.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Gufic Biosciences stood at ₹3,021.5 Cr

The latest P/E ratio of Gufic Biosciences as of 16-Apr-2026 is 59.78.

The latest P/B ratio of Gufic Biosciences as of 16-Apr-2026 is 4.69.

The 52-week high of Gufic Biosciences is ₹409.0 and the 52-week low is ₹267.5.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gufic Biosciences is ₹893 ( Cr.) .

About Gufic Biosciences Ltd

The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

Pharmaceutical
Herbal
API / Bulk Drugs
Personal care
International

History and milestone

Past Initiatives

First Indian to produce Doxycycline Inj.
First Indian company to make Liquid Oxytetracycline Inj.
Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
First Company to launch Boswellia Serrata tablets
Pioneer in developing Kid tablet in India
Hived off Mox and Zole to Ranbaxy

2007-2009

Initiated contract manufacturing
Commenced international exports

2010-2015

Received patents for Anidulafungin and Tigecycline lyophilized inj.
Launched Criticare division

2016

Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
Launched Ferticare and Criticare Life divisions

2017-2019

Received patents for Rifabutin and Micafunginlyophilized inj.
Exported Vancomycin lyophilized Inj. to Germany
Manufacturing capacity ramped up to 31 million vials per annum
Launched Ferticare Life division

2020

Manufacturing Remdesivir for Hetero
Increased capacity to 48 million vials per annum

2022

Incorporated wholly owned subsidiary company namely ‘Gufic UK’
Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Gufic Biosciences Ltd (GUFICBIO) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Gufic Biosciences Share Price